Policy & Regulation
AmpliPhi Biosciences Prices Public Offering of Common Stock at USD 1.00 Per Share
12 January 2018 - - San Diego, California-based developer of therapies for antibiotic-resistant infections using bacteriophage-based technology AmpliPhi Biosciences Corp. (NYSE MKT: APHB) has priced a public offering of 4m shares of its common stock, offered at a price to the public of USD 1.00 per share, for gross proceeds of USD 4m, before deducting placement agent fees and offering expenses payable by AmpliPhi, the company said.
The offering is expected to close on or about January 12, 2018, subject to customary closing conditions.
AmpliPhi intends to use the net proceeds from the offering for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development expenses and general and administrative expenses.
AmpliPhi Biosciences is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology.
Its lead product candidates target multidrug-resistant S. aureus and P. aeruginosa, which are included on the World Health Organization's 2017 Priority Pathogens List.